Výsledky vyhledávání - "K L, Nathanson"

Abstract P5-10-04: Spectrum of hereditary breast and ovarian cancer gene variants in an African American cohort

Autor: Payal D. Shah, A. R. Bradbury, J. van den Akker, E Gil, Simon, Kara N. Maxwell, S Kim, Susan M. Domchek, Laura DiGiovanni, K. L. Nathanson

Publikováno v: Cancer Research. 77:P5-10

Background: Few reports describe the spectrum of mutations in breast and ovarian cancer predisposition genes found specifically in African Americans. Methods: 560 women who self-identified as African American (AA) from the University of Pennsylvania

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e19a1d458fe39f575780e26de95d8c8f
https://doi.org/10.1158/1538-7445.sabcs16-p5-10-04

Zobrazit plný text záznamu

Abstract P2-09-01: Patient reported outcomes of multiplex breast cancer susceptibility testing utilizing a tiered-binned counseling and informed consent model in BRCA1/2 negative patients

Autor: Jill E. Stopfer, Susan M. Domchek, Kara N. Maxwell, Jessica M. Long, Amanda Brandt, A. R. Bradbury, K. L. Nathanson, Linda Patrick-Miller, Laura DiGiovanni, BE Egleston, Jamie Brower, Jacquelyn Powers

Publikováno v: Cancer Research. 76:P2-09

Background:The risks, benefits and utilities of multiplex panels for breast cancer susceptibility are unknown and new counseling and informed consent models are needed. We sought to obtain patient reported outcomes of multiplex testing in BRCA1/2 neg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d7af8fe65af51744b86c7b6958618996
https://doi.org/10.1158/1538-7445.sabcs15-p2-09-01

Zobrazit plný text záznamu

A single arm phase II study of rucaparib maintenance in patients with advanced pancreatic adenocarcinoma and a known deleterious BRCA1, BRCA2 or PALB2 mutation who have achieved stability on platinum therapy

Autor: Rosemarie Mick, Ursina R. Teitelbaum, Kara N. Maxwell, Charles J. Schneider, Mark H. O'Hara, Kim A. Reiss, Susan M. Domchek, Peter J. O'Dwyer, Erica L. Carpenter, K. L. Nathanson

Publikováno v: Journal of Clinical Oncology. 36:TPS531-TPS531

TPS531 Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a median overall survival of < 1 year. A subset of PDAC is characterized by a homologous recombination deficiency (HRD). The most well-defined patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::11713696c3a107f38766f83f96aa609d
https://doi.org/10.1200/jco.2018.36.4_suppl.tps531

Zobrazit plný text záznamu

The Role of BRAF Mutation and p53 Inactivation during Transformation of a Subpopulation of Primary Human Melanocytes

Autor: Phyllis A. Gimotty, Hong Yu, Patricia A. Possik, Mcdaid Ronan, John T. Lee, Maria Dalla Palma, David E. Elder, K. L. Nathanson, Matthew Guerra, Patricia Van Belle, Suresh M. Kumar, Ling Li, Meenhard Herlyn, Xiaowei Xu, Rachel Hammond

Publikováno v: The American Journal of Pathology. 174:2367-2377

Melanocytic nevi frequently harbor oncogenic BRAF mutations, but only a minority progress to melanoma. In human melanocytes, persistent BRAF(V600E) expression triggers oncogene-induced senescence, which implies that bypass of oncogene-induced senesce

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4836598138c5b779f408b50a9f377062
https://doi.org/10.2353/ajpath.2009.081057

Zobrazit plný text záznamu

Abstract P6-07-05: Mutational spectrum and tumor response in metastatic breast cancer

Autor: Michael Feldman, Kara N. Maxwell, Carolyn E. Clark, Andrea B. Troxel, David B. Lieberman, Angela R. Bradbury, John H. Glick, Danielle Soucier-Ernst, J. Morrissette, Susan M. Domchek, AM DeMichele, Kevin Fox, N Shih, Jennifer M. Matro, K. L. Nathanson, Amy S. Clark, Noah Goodman, Christopher Colameco, Lewis A. Chodosh

Publikováno v: Cancer Research. 76:P6-07

Background: While several comprehensive genomic sequencing tests are clinically available for breast cancer(BC), little is known about the spectrum of findings reported in the general population and clinical utility of findings for patients(pts). Her

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8dc127012e751007e7eb7825c9304f95
https://doi.org/10.1158/1538-7445.sabcs15-p6-07-05

Zobrazit plný text záznamu

Breast cancer genetics: What we know and what we need

Autor: K L, Nathanson, R, Wooster, B L, Weber, K N, Nathanson

Publikováno v: Nature Medicine. 7:552-556

Breast cancer results from genetic and environmental factors leading to the accumulation of mutations in essential genes. Genetic predisposition may have a strong, almost singular effect, as with BRCA1 and BRCA2, or may represent the cumulative effec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eee6d7b58a21520d4c963c2a7f9ea46
https://doi.org/10.1038/87876

Zobrazit plný text záznamu

Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation–positive metastatic melanoma patients (pts)

Autor: Keith T. Flaherty, Olivia Spleiss, Astrid Koehler, J. A. Sosman, I. Puzanov, Rebecca Lee, K. B. Kim, A. Ribas, W. Wu, Kerstin Trunzer, Paul B. Chapman, Grant A. McArthur, Gideon Bollag, K. L. Nathanson

Publikováno v: Journal of Clinical Oncology. 29:8502-8502

8502 Background: Vemurafenib (PLX4032), an oral, selective inhibitor of oncogenic V600E mutant BRAF, was evaluated for safety and pharmacokinetics in the Phase I dose escalation (DE) study PLX06-02 (Flaherty, et al. NEJM, 2010). Exploratory analyses

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::65a3fe4b938dec346c32f0b18ce1a3b9
https://doi.org/10.1200/jco.2011.29.15_suppl.8502

Zobrazit plný text záznamu

Abstract 659: Overexpression of TPX2 accelerates cell cycle progression in melanoma and is an indicator of response to Aurora A kinase inhibitors

Autor: M. Dalla Palma, Keiran S.M. Smalley, George Xu, Bin Li, Meenhard Herlyn, K. L. Nathanson

Publikováno v: Cancer Research. 70:659-659

There is a tremendous need to identify more effective treatments for metastatic melanoma. In order to detect genetic changes in melanoma that might facilitate the development of novel therapies, we performed aCGH in melanoma cell lines and tumors and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6923e882c0753e4ca3abde5e1e2e0849
https://doi.org/10.1158/1538-7445.am10-659

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání